CNS Pharmaceuticals
Singer Island, United States
Hematologist/Oncologist who earned a BA, ScM, PhD, from the Johns Hopkins University School of Arts and Sciences, the School of Public Health, and the School of Medicine, respectively, in Baltimore, MD, after which she did a fellowship at the Johns Hopkins Hospital. Received her MD from Cornell University Medical College in New York City and then completed both a clinical fellowship in Hematology/Oncology as well as a research fellowship in tumor immunology at the Brigham & Women's Hospital and the Dana Farber Cancer Institute in Boston, MA. She continued to do basic research in Boston after being granted a Clinical Investigator Award from the National Institutes of Health and was an Instructor in Medicine at Harvard Medical School. She subsequently served as an attending physician at Yale University Hospital in New Haven, CT, as well as in the Duke Hematology/Oncology Program.
Her career in drug development began at Pfizer, Inc., performing the initial clinical trials of erlotinib. She then led the global clinical development of imatinib at Novartis for both CML and GIST, and was the Vice President and Global Therapeutic Area Head in Oncology at Eisai, developing their primary drugs in oncology including eribulin and lenvatinib.
She is currently the managing partner in a consulting company providing guidance for biotechnology and pharmaceutical companies. She is involved in advancing new therapies through translational research, clinical trial designs, leading later development programs, as well as serving as the chief medical officer and scientific advisor in several companies. Throughout her career in the industry she has continued to work part-time in active clinical practice, and until recently was an attending physician in the Duke Fellowship Program at the Veteran’s Administration Medical Center Hematology/Oncology clinic in Durham, NC. She is currently located in Palm Beach County in Florida.